Professor of immunotechnology at Aix-Marseille University (AMU) and co-founder of Innate Pharma, François Romagné contributed to the creation of MI-mAbs, where he has been the Scientific Director ever since. He brings his knowledge and his experience of antibodies, both in diagnostics (14 years spent within the immunodiagnostic company Immunotech) and in therapeutic applications (14 years as Chief Scientific Officer of Innate Pharma of whom he is now members of Scientific Advisory Board).
François is the author of over 50 scientific publications and 15 patents.
Stéphanie Blanchin boasts a long experience in development and characterization of monoclonal antibodies for diagnostics (CHU de Caen) as well as therapeutic purposes (PX'Therapeutics). After her PhD in Immunology at Aix-Marseille Université (AMU), she pursued a postdoctoral internship in the Department of Medical Biochemistry at Cardiff University before joining the laboratory of Immunology and immunopathology of the CHU of Caen. Building on her experience and before joining MI-mAbs, she started and directed a platform dedicated to the generation of therapeutic monoclonal antibodies within the biotechnology company PX’Therapeutics.
Laurent POUYET has a long experience using in vitro and in vivo models for the validation of drug candidates in cancer and inflammation. He holds a PhD in Immunology from Aix-Marseille Université (AMU) during which he worked at the Immunology Center of Marseille-Luminy (CIML). Laurent POUYET was then a postdoctoral fellow first at the University of California San Francisco (UCSF), thenat the Marseille Cancer Research Center (CRCM) where he developed several models to reproduce the biological mechanisms involved in cancer and inflammatory diseases. Building on his experience, he worked at TrGET, the pre-clinical assay platform of the Paoli-Calmettes Institute (IPC) before joining MI-mAbs.
Agnès MENUT studied at the University of Montpellier- Faculty of Pharmacy followed by a Master’s degree specialized in Large Project Management in a Commercial School (HEC /SUPAERO). Agnès MENUT has over 10 years of experience in the pharmaceutical industry (Sanofi), notably in various projects in research (candidate validation) and development (phase 1 up to projects in Application Submission phase), in Oncology and Neurodegenerative Disease as project Manager/Leader. She worked for 2 years in external innovation in the Biotechnology unit of Sanofi.
Patrick VLIEGHE holds a Ph.D. degree in Medicinal Chemistry and a Master’s degree specialized in Healthcare Company Management at Euromed Management (now KEDGE Business School). He has over 20 years of experience in pharma/biotech, technology transfer and financing of innovation, working notably on various projects at the interface of science and business development. Among several experiences, he was Head of Development at Vect-Horus (a drug targeting company), and Technology Transfer Manager (SATT Sud-Est, a Technology Transfer Office).